← Leaderboards
Brent Allen Hanks
Duke University
$4,918,964
Attributed
$4,918,964
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $911.5K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,918,964 · 3
By mechanism
R37$2,538,820 · 1
R01$1,554,484 · 1
K08$825,660 · 1
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Mikhail Nikiforov$14,564,827
- Rasheed Adebayo Gbadegesin$10,821,739
- Xiao-Fan Wang$23,927,835
- David Reardon$8,732,934
- Zachary Conrad Hartman$2,643,521
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseTumorPathway InteractionsMediatingSignal TransductionImmunotherapyMelanomaImmunotherapeutic AgentInsightImmune Checkpoint InhibitorCd8-Positive T-LymphocytesAnti-Pd1 AntibodiesMutationAntibody ImmunotherapyOncologyInflammasomeChemokineHeat-Shock Proteins 70In VitroCancer PatientGeneticClinical ResearchAutomobile DrivingIn Vivo
Grant awards (20)
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy$617,715
R37 · FY2025 · CA · contact PI
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities$263,831
R01 · FY2024 · CA · contact PI
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities$209,670
R01 · FY2024 · CA · contact PI
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy$188,323
R37 · FY2024 · CA · contact PI
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy$120,164
R37 · FY2024 · CA · contact PI
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy$327,396
R37 · FY2023 · CA · contact PI
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities$297,705
R01 · FY2023 · CA · contact PI
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities$386,846
R01 · FY2022 · CA · contact PI
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy$320,179
R37 · FY2022 · CA · contact PI
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy$132,629
R37 · FY2022 · CA · contact PI
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities$396,432
R01 · FY2021 · CA · contact PI
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy$321,515
R37 · FY2021 · CA · contact PI
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy$132,629
R37 · FY2021 · CA · contact PI
Exploration of Tumor-Intrinsic NLRP3 Signaling Regulators$60,897
R37 · FY2021 · CA · contact PI
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy$317,373
R37 · FY2020 · CA · contact PI
Melanoma-mediated Dendritic Cell Tolerization and Immune Evasion$165,132
K08 · FY2019 · CA · contact PI
Melanoma-mediated Dendritic Cell Tolerization and Immune Evasion$165,132
K08 · FY2018 · CA · contact PI
Melanoma-mediated Dendritic Cell Tolerization and Immune Evasion$165,132
K08 · FY2017 · CA · contact PI
Melanoma-mediated Dendritic Cell Tolerization and Immune Evasion$165,132
K08 · FY2016 · CA · contact PI
Melanoma-mediated Dendritic Cell Tolerization and Immune Evasion$165,132
K08 · FY2015 · CA · contact PI